| Mr Matthew David Muller, PHD, CAA | |
|
11100 Euclid Ave Dept Of, Cleveland, OH 44106-1716 | |
| (216) 844-8077 | |
| Not Available |
| Full Name | Mr Matthew David Muller |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology Assistant |
| Experience | 6 Years |
| Location | 11100 Euclid Ave Dept Of, Cleveland, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962907972 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Hospitals Ahuja Medical Center | Beachwood, OH | Hospital |
| University Hospitals Of Cleveland | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Hospitals Medical Group Inc | 4789682493 | 1466 |
| University Primary Care Practices Inc | 3072417534 | 940 |
News Archive
Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2011 taking place November 8-13, 2011 in Philadelphia, Pa.
Free-flowing cancer cells have been mapped with unprecedented accuracy in the bloodstream of patients with prostate, breast and pancreatic cancer, using a brand new approach, in an attempt to assess and control the disease as it spreads in real time through the body, and solve the problem of predicting response and resistance to therapies.
Today the University of Colorado and The Anna and John J. Sie Foundation of Denver announced The Sie Family Down Syndrome Break-Through Research Initiative. The initiative will provide $600,000 in grant funds to stimulate new scientific research on Down syndrome with the aim of enhancing cognitive ability. These are the first such grants provided to CU for a specific chromosomal condition and the first nationwide specifically for Down syndrome.
Bristol-Myers Squibb Company today announced positive results from a randomized Phase 2 study evaluating ipilimumab in combination with standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer.
States that expanded eligibility for their Medicaid program in 2014 when the Affordable Care Act was implemented, saw fewer uninsured patients among major cardiac-related hospitalizations in the first year compared with states that did not expand the program, according to a study released today in JAMA Network Open.
› Verified 6 days ago
| Entity Name | University Primary Care Practices Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003935339 PECOS PAC ID: 3072417534 Enrollment ID: O20031125000767 |
News Archive
Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2011 taking place November 8-13, 2011 in Philadelphia, Pa.
Free-flowing cancer cells have been mapped with unprecedented accuracy in the bloodstream of patients with prostate, breast and pancreatic cancer, using a brand new approach, in an attempt to assess and control the disease as it spreads in real time through the body, and solve the problem of predicting response and resistance to therapies.
Today the University of Colorado and The Anna and John J. Sie Foundation of Denver announced The Sie Family Down Syndrome Break-Through Research Initiative. The initiative will provide $600,000 in grant funds to stimulate new scientific research on Down syndrome with the aim of enhancing cognitive ability. These are the first such grants provided to CU for a specific chromosomal condition and the first nationwide specifically for Down syndrome.
Bristol-Myers Squibb Company today announced positive results from a randomized Phase 2 study evaluating ipilimumab in combination with standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer.
States that expanded eligibility for their Medicaid program in 2014 when the Affordable Care Act was implemented, saw fewer uninsured patients among major cardiac-related hospitalizations in the first year compared with states that did not expand the program, according to a study released today in JAMA Network Open.
› Verified 6 days ago
| Entity Name | University Hospitals Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669499414 PECOS PAC ID: 4789682493 Enrollment ID: O20061113000301 |
News Archive
Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2011 taking place November 8-13, 2011 in Philadelphia, Pa.
Free-flowing cancer cells have been mapped with unprecedented accuracy in the bloodstream of patients with prostate, breast and pancreatic cancer, using a brand new approach, in an attempt to assess and control the disease as it spreads in real time through the body, and solve the problem of predicting response and resistance to therapies.
Today the University of Colorado and The Anna and John J. Sie Foundation of Denver announced The Sie Family Down Syndrome Break-Through Research Initiative. The initiative will provide $600,000 in grant funds to stimulate new scientific research on Down syndrome with the aim of enhancing cognitive ability. These are the first such grants provided to CU for a specific chromosomal condition and the first nationwide specifically for Down syndrome.
Bristol-Myers Squibb Company today announced positive results from a randomized Phase 2 study evaluating ipilimumab in combination with standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer.
States that expanded eligibility for their Medicaid program in 2014 when the Affordable Care Act was implemented, saw fewer uninsured patients among major cardiac-related hospitalizations in the first year compared with states that did not expand the program, according to a study released today in JAMA Network Open.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Matthew David Muller, PHD, CAA 29241 Beechwood Dr, Wickliffe, OH 44092-2040 Ph: (419) 304-7356 | Mr Matthew David Muller, PHD, CAA 11100 Euclid Ave Dept Of, Cleveland, OH 44106-1716 Ph: (216) 844-8077 |
News Archive
Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2011 taking place November 8-13, 2011 in Philadelphia, Pa.
Free-flowing cancer cells have been mapped with unprecedented accuracy in the bloodstream of patients with prostate, breast and pancreatic cancer, using a brand new approach, in an attempt to assess and control the disease as it spreads in real time through the body, and solve the problem of predicting response and resistance to therapies.
Today the University of Colorado and The Anna and John J. Sie Foundation of Denver announced The Sie Family Down Syndrome Break-Through Research Initiative. The initiative will provide $600,000 in grant funds to stimulate new scientific research on Down syndrome with the aim of enhancing cognitive ability. These are the first such grants provided to CU for a specific chromosomal condition and the first nationwide specifically for Down syndrome.
Bristol-Myers Squibb Company today announced positive results from a randomized Phase 2 study evaluating ipilimumab in combination with standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer.
States that expanded eligibility for their Medicaid program in 2014 when the Affordable Care Act was implemented, saw fewer uninsured patients among major cardiac-related hospitalizations in the first year compared with states that did not expand the program, according to a study released today in JAMA Network Open.
› Verified 6 days ago
Shannon Kelly, AA-C Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Olivia Kehoe, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-1000 | |
Brian Michael Wheatley, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Nicole M Moses, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Michael Marcotte, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Thomas Bruno, AA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-7330 | |
Gregory G Kychun, AA Anesthesiologist Assistant Medicare: Not Enrolled in Medicare Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-7330 |